The CDC Colorectal Cancer Control Program, 2009–2015

Joseph, Djenaba; DeGroff, Amy

doi:10.5888/pcd16.190336

Cited by 12 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CDC's colorectal cancer screening program has provided funding for practice facilitation and screening services that support mailed FIT outreach in a variety of clinics throughout the United States. 60,61 Notably, long-term sustainability of the Cancer Prevention and Research Institute and CDC programs is subject to the availability of funds and policy directives, suggesting that more robust solutions are needed to ensure the sustainability of programs sponsored by these entities.…”

Section: Kq8: What Strategies Can Be Used To Ensure the Sustainabilitmentioning

confidence: 99%

Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit

Gupta

Coronado

Argenbright

et al. 2020

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Uptake of colorectal cancer screening remains suboptimal. Mailed fecal immunochemical testing (FIT) offers promise for increasing screening rates, but optimal strategies for implementation have not been well synthesized. In June 2019, the Centers for Disease Control and Prevention convened a meeting of subject matter experts and stakeholders to answer key questions regarding mailed FIT implementation in the United States. Points of agreement included: 1) primers, such as texts, telephone calls, and printed mailings before mailed FIT, appear to contribute to effectiveness; 2) invitation letters should be brief and easy to read, and the signatory should be tailored based on setting; 3) instructions for FIT completion should be simple and address challenges that may lead to failed laboratory processing, such as notation of collection date; 4) reminders delivered to initial noncompleters should be used to increase the FIT return rate; 5) data infrastructure should identify eligible patients and track each step in the outreach process, from primer delivery through abnormal FIT follow‐up; 6) protocols and procedures such as navigation should be in place to promote colonoscopy after abnormal FIT; 7) a high‐quality, 1‐sample FIT should be used; 8) sustainability requires a program champion and organizational support for the work, including sufficient funding and external policies (such as quality reporting requirements) to drive commitment to program investment; and 9) the cost effectiveness of mailed FIT has been established. Participants concluded that mailed FIT is an effective and efficient strategy with great potential for increasing colorectal cancer screening in diverse health care settings if more widely implemented.

show abstract

Section: Kq8: What Strategies Can Be Used To Ensure the Sustainabilitmentioning

confidence: 99%

Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit

Gupta

Coronado

Argenbright

et al. 2020

CA A Cancer J Clinicians

View full text Add to dashboard Cite

show abstract

“…This could therefore could improve early diagnosis and intervention for CRC, a key objective of public health policy internationally. 4 , 56 …”

Section: Discussionmentioning

confidence: 99%

Long-term conditions, multimorbidity and colorectal cancer risk in the UK Biobank cohort

Corcoran

Mair

Nicholl

et al. 2022

Journal of Multimorbidity and Comorbidity

View full text Add to dashboard Cite

Purpose Early identification of colorectal cancer (CRC) is an international priority. Multimorbidity (presence of ≥2 long-term conditions (LTCs)) is increasing and the relationship between CRC and LTCs is little-understood. This study explores the relationship between individual LTCs, multimorbidity and CRC incidence and mortality. Methods Longitudinal analysis of the UK Biobank cohort, participants recruited 2006–2010; N = 500,195; excluding previous CRC at baseline. Baseline data was linked with cancer/mortality registers. Demographic characteristics, lifestyle factors, 43 LTCs, CRC family history, non-CRC cancers, and multimorbidity count were recorded. Variable selection models identified candidate LTCs potentially predictive of CRC outcomes and Cox regression models tested for significance of associations between selected LTCs and outcomes. Results Participants’ age range: 37–73 (mean age 56.5; 54.5% female). CRC was diagnosed in 3669 (0.73%) participants, and 916 (0.18%) died from CRC during follow-up (median follow-up 7 years). CRC incidence was higher in the presence of heart failure (Hazard Ratio (HR) 1.96, 95% Confidence Interval (CI) 1.13–3.40), diabetes (HR 1.15, CI 1.01–1.32), glaucoma (HR 1.36, CI 1.06–1.74), male cancers (HR 1.44, CI 1.01–2.08). CRC mortality was higher in presence of epilepsy (HR 1.83, CI 1.03–3.26), diabetes (HR 1.32, CI 1.02–1.72), osteoporosis (HR 1.67, CI 1.12–2.58). No significant association was found between multimorbidity (≥2 LTCs) and CRC outcomes. Conclusions The associations of certain LTCs with CRC incidence and mortality has implications for clinical practice: presence of certain LTCs in patients presenting with CRC symptoms could trigger early investigation and diagnosis. Future research should explore causative mechanisms and patient perspectives.

show abstract

“…For each person served by the CRCCP, grantees collected a standardized set of CRC clinical data from the medical record outlined in the CDC CRCCP Data User's Manual [26,27]. Demographic information included age, sex, personal history of colorectal polyps or CRC, prior CRC screening before CRCCP enrollment, income, family history of CRC, and CRCCP eligibility, i.e., those whose annual household income was ≤250% of the federal poverty level and were uninsured or underinsured for CRC screening services.…”

Section: Data Elementsmentioning

confidence: 99%

Clinical Outcomes from the Alaska Native Tribal Health Consortium Colorectal Cancer Control Program: 2009–2015

Nash,

Verhage,

Flanagan

et al. 2024

IJERPH

View full text Add to dashboard Cite

The Alaska Native Tribal Health Consortium (ANTHC) participated in the United States Centers for Disease Control and Prevention Colorectal Cancer Control Program (CRCCP) from 2009 to 2015. We conducted a descriptive evaluation of ANTHC CRCCP demographics, quality measures, and clinical outcomes, including screening methods employed within the program and screening outcomes. There were 6981 program screenings completed, with the majority (81.3%) of people screened in the 50–75 year age group. Colonoscopy was the primary screening test used, accounting for 6704 (96.9%) of the screening tests. Quality of colonoscopy was high: adequate bowel preparation was reported in 98.2% of colonoscopies, cecal intubation rate was 98.9%, and the adenoma detection rate was 38.9%. A high proportion (58.9%) of colonoscopies had an initial finding of polyps or lesions suspicious for cancer; 41.2% of all colonoscopies had histological confirmation of either adenomatous polyps (40.6%) or cancer (0.5%). The ANTHC CRCCP successfully increased CRC screening among American Indian and Alaska Native peoples living in Alaska; this was achieved primarily through high-quality colonoscopy metrics. These data support a continued focus by the Alaska Native Tribal Health Consortium and its tribal health partners on increasing CRC screening and reducing cancer mortality among Alaska Native peoples.

show abstract

The CDC Colorectal Cancer Control Program, 2009–2015

Cited by 12 publications

References 17 publications

Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit

Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention–sponsored Summit

Long-term conditions, multimorbidity and colorectal cancer risk in the UK Biobank cohort

Clinical Outcomes from the Alaska Native Tribal Health Consortium Colorectal Cancer Control Program: 2009–2015

Contact Info

Product

Resources

About